Compare ATER & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATER | AKTX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.5M |
| IPO Year | 2019 | 2014 |
| Metric | ATER | AKTX |
|---|---|---|
| Price | $1.13 | $16.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | 693.9K | ★ 1.4M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,975,000.00 | N/A |
| Revenue This Year | $16.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.12 |
| 52 Week High | $1.87 | $29.32 |
| Indicator | ATER | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 64.60 |
| Support Level | $0.59 | $0.69 |
| Resistance Level | $1.32 | N/A |
| Average True Range (ATR) | 0.11 | 3.78 |
| MACD | -0.02 | 1.53 |
| Stochastic Oscillator | 27.94 | 49.90 |
Aterian Inc is a consumer products company that operates through online retail channels, including Amazon, Walmart, Target, as well as its own direct-to-consumer websites. The company develops and manages a portfolio of owned brands, which are either internally incubated or acquired, offering products across multiple categories such as home and kitchen appliances, kitchenware, air quality appliances, health and beauty products, and essential oils. Its primary brands include Squatty Potty, HomeLabs, Mueller Living, PurSteam, Healing Solutions, and Photo Paper Direct. The company generates revenue mainly through the online sale of its consumer products, with substantially all sales derived from the Amazon U.S. marketplace.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.